Cathelicidin antimicrobial peptide expression in neutrophils and neurons antagonistically modulates neuroinflammation
Journal of Clinical Investigation · 03.02.2025 · 135 (3)
DOI: 10.1172/jci184502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 10.12.2024. Verfasst von Subash Chand Verma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, CNRS, INSERM, Institut Necker Enfants Malades-INEM, Paris, France. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Neutrophils, Neurons, Cathelicidins. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation pour l’Aide à la recherche sur la Sclérose en Plaques.
Abstract (Originalsprache)
Multiple sclerosis (MS) is an autoimmune disease that affects the CNS, the pathophysiology of which remains unclear and for which there is no definitive cure. Antimicrobial peptides (AMPs) are immunomodulatory molecules expressed in various tissues, including the CNS. Here, we investigated whether the cathelicidin-related AMP (CRAMP) modulated the development of experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. We showed that, at an early stage, CNS-recruited neutrophils produced neutrophil extracellular traps (NETs) rich in CRAMP that were required for EAE initiation. NET-associated CRAMP stimulated IL-6 production by dendritic cells via the cGAS/STING pathway, thereby promoting encephalitogenic Th17 response. However, at a later disease stage, neurons also expressed CRAMP that reduced EAE severity. Camp knockdown in neurons led to disease exacerbation, while local injection of CRAMP 1–39 at the peak of EAE promoted disease remission. In vitro, CRAMP 1–39 regulated the activation of microglia and astrocytes through the formyl peptide receptor (FPR) 2. Finally, administration of butyrate, a gut microbiota-derived metabolite, stimulated the expression of neural CRAMP via the free fatty acids receptors 2/3 (FFAR2/3), and prevented EAE. This study shows that CRAMP produced by different cell types has opposing effects on neuroinflammation, offering therapeutic opportunities for MS and other neuroinflammatory disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, CNRS, INSERM, Institut Necker Enfants Malades-INEM, Paris, France.
- Université Paris Cité, Imagine Institute, INSERM U1163, Paris, France.
- APHP, Hôpital Necker-Enfants Malades, Paris, France.
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), CNRS, INSERM, Université Paul-Sabatier de Toulouse (UPS), Toulouse, France.
- Department of Immunology, Toulouse University Hospital, Toulouse, France.
Förderung
- Fondation pour l’Aide à la recherche sur la Sclérose en Plaques
Zitieren
APA
Verma, S. C., Enée, E., Manasse, K., Rebhi, F., Penc, A., Romeo-Guitart, D., Bui Thi, C., Titeux, M., Oury, F., Fillatreau, S., Liblau, R., & Diana, J. (2025). Cathelicidin antimicrobial peptide expression in neutrophils and neurons antagonistically modulates neuroinflammation. Journal of Clinical Investigation, 135(3). https://doi.org/10.1172/jci184502
Vancouver
Verma SC, Enée E, Manasse K, Rebhi F, Penc A, Romeo-Guitart D, et al. Cathelicidin antimicrobial peptide expression in neutrophils and neurons antagonistically modulates neuroinflammation. Journal of Clinical Investigation. 2025;135(3). doi:10.1172/jci184502
BibTeX
@article{Verma2025,
author = {Verma, Subash Chand and Enée, Emmanuelle and Manasse, Kanchanadevi and Rebhi, Feriel and Penc, Axelle and Romeo-Guitart, David and Bui Thi, Cuc and Titeux, Matthias and Oury, Franck and Fillatreau, Simon and Liblau, Roland and Diana, Julien},
title = {Cathelicidin antimicrobial peptide expression in neutrophils and neurons antagonistically modulates neuroinflammation},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {3},
doi = {10.1172/jci184502}
}
EUVIMED